Immune Design (NASDAQ:IMDZ)‘s stock had its “buy” rating reiterated by research analysts at Cowen in a report issued on Monday.
A number of other equities analysts have also recently issued reports on IMDZ. Royal Bank of Canada assumed coverage on shares of Immune Design in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective on the stock. ValuEngine lowered shares of Immune Design from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Wells Fargo & Company lowered shares of Immune Design from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. Finally, Zacks Investment Research upgraded shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Monday, November 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Immune Design has an average rating of “Hold” and a consensus price target of $13.19.
Immune Design (IMDZ) opened at $3.75 on Monday. Immune Design has a 1 year low of $3.55 and a 1 year high of $13.05.
Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.11. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. analysts expect that Immune Design will post -1.89 earnings per share for the current year.
In other Immune Design news, major shareholder Leo Guthart acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average price of $9.70 per share, with a total value of $97,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Peter Svennilson acquired 2,681,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 5,300,000 shares of company stock worth $21,874,900. 20.70% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in shares of Immune Design by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 1,600 shares during the last quarter. California State Teachers Retirement System increased its holdings in Immune Design by 8.3% during the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 2,300 shares during the last quarter. Trexquant Investment LP increased its holdings in Immune Design by 15.5% during the second quarter. Trexquant Investment LP now owns 31,152 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 4,174 shares during the last quarter. Teachers Advisors LLC increased its holdings in Immune Design by 23.0% during the second quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 5,181 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Immune Design by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 6,896 shares in the last quarter. Hedge funds and other institutional investors own 29.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://ledgergazette.com/2017/12/13/immune-design-imdz-rating-reiterated-by-cowen.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.